Guntinas-Lichius Orlando, Wendt Thomas G, Kornetzky Nicole, Buentzel Jens, Esser Dirk, Böger Daniel, Müller Andreas, Schultze-Mosgau Stefan, Schlattmann Peter, Schmalenberg Harald
Department of Otorhinolaryngology, Jena University Hospital, Jena, Germany.
Department of Radiooncology, Jena University Hospital, Jena, Germany.
Oral Oncol. 2014 Dec;50(12):1157-64. doi: 10.1016/j.oraloncology.2014.09.015. Epub 2014 Oct 19.
The objective of this study was to examine patterns of care and survival in a population-based sample of patients with head neck cancer (HNC) who were treated in Thuringia, a federal state in Germany, between 1996 and 2011.
Data of 6291 patients with primary HNC from the Thuringian cancer registry were used to evaluate for patient's characteristics, tumor stage, incidence, and trends in treatment and overall survival (OS).
The distribution between stages I-IV did not change significantly during the observation period. Crude incidences of HNC increased significantly between 1996 and 2011 from 13.77 to 20.39 (relative risk [RR]=1.34; 95% confidence interval [CI]=1.25-1.45). This increase was mainly driven by a significant increase of oropharynx cancer (from 3.29 to 5.85; RR=1.67; 95%CI=1.49-1.88) and cancer of the oral cavity (3.41-5.90; RR=1.5; 95%CI=1.33-1.69). The relative frequency of multimodal therapy increased (RR=1.42; 95%CI=1.3-1.55). The use of cetuximab increased (RR=473.32; 95%CI=51.57-4344.51). The 5-year and 10-year OS for the entire cohort was 49.1% and 34.1%, respectively. The multivariable analysis has proven that male gender, age ⩾60years, therapy without surgery, and TNM stage were independent significant negative risk factors for OS (all p<0.0001).
OS did not improve during the study period. Incidence of oral cancer is significantly increasing. Although modern treatment strategies have been included in routine HNC care over the time, outcome has not improved significantly.
本研究的目的是调查1996年至2011年间在德国图林根州接受治疗的以人群为基础的头颈癌(HNC)患者样本中的护理模式和生存率。
来自图林根癌症登记处的6291例原发性HNC患者的数据用于评估患者特征、肿瘤分期、发病率以及治疗和总生存期(OS)的趋势。
在观察期内,I-IV期之间的分布没有显著变化。1996年至2011年间,HNC的粗发病率从13.77显著增加到20.39(相对风险[RR]=1.34;95%置信区间[CI]=1.25-1.45)。这种增加主要是由口咽癌(从3.29增加到5.85;RR=1.67;95%CI=1.49-1.88)和口腔癌(从3.41增加到5.90;RR=1.5;95%CI=1.33-1.69)的显著增加所驱动。多模式治疗的相对频率增加(RR=1.42;95%CI=1.3-1.55)。西妥昔单抗的使用增加(RR=473.32;95%CI=51.57-4344.51)。整个队列的5年和10年OS分别为49.1%和34.1%。多变量分析已证明男性、年龄≥60岁、非手术治疗以及TNM分期是OS的独立显著负性风险因素(所有p<0.0001)。
在研究期间,OS没有改善。口腔癌的发病率显著增加。尽管随着时间的推移,现代治疗策略已被纳入常规HNC护理中,但结果并未显著改善。